ApoA-1 infusion reduces arterial cholesterol and myocardial lesions in a rat model of cardiac dysfunction and insulin resistance

Atherosclerosis

Volumn 222, Issue 2, 2012, Pages 402-408

  Borthwick, Faye ^a   Warnakula, Samantha ^a   Mangat, Rabban ^a   Uwiera, Richard R ^a   Russell, James C ^a   Kelly, Sandra E ^a,b   Lee, Candace Y ^c   Hryshko, Larry ^c   Mamo, John C L ^g   Rye, Kerry Anne ^d,e,f   Lopaschuk, Gary D ^b   Proctor, Spencer D ^a  

^a Mazankowski Alberta Heart Institute   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ST BONIFACE GENERAL HOSPITAL   (Canada)

^d HEART RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF WESTERN SYDNEY   (Australia)

^g CURTIN UNIVERSITY   (Australia)

Author keywords

Apolipoprotein A1; Arterial cholesterol; Cardiac dysfunction; High density lipoprotein; Insulin resistance

Indexed keywords

APOLIPOPROTEIN A1; EOSIN; HEMATOXYLIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL CHOLESTEROL DEPOSITION; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL COMPLIANCE; BLOOD VESSEL PARAMETERS; CARDIOVASCULAR DISEASE; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DIASTOLE; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; EX VIVO STUDY; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE INJURY; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RAT; REDUCTION; STAINING;

ANIMALS; APOLIPOPROTEIN A-I; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CHOLESTEROL; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY, DOPPLER; HUMANS; INFUSIONS, PARENTERAL; INSULIN RESISTANCE; LIPOPROTEINS, HDL; MALE; METABOLIC SYNDROME X; MYOCARDIUM; OBESITY; RATS; RATS, WISTAR; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84861345342     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.03.006     Document Type: Article

References (41)

1. Meetoo D. Chronic diseases: the silent global epidemic. Br J Nurs 2008, 17(21):1320-1325.
2. Mooradian A.D. Cardiovascular disease in type 2 diabetes mellitus: current management guidelines. Arch Intern Med 2003, 163:33-40.
3. Vessby B. Dietary fat, fatty acid composition in plasma and the metabolic syndrome. Curr Opin Lipidol 2003, 14:15-19.
4. Bhattachacharyya O.K., Shah B.R., Booth G.L. Management of cardiovascular disease in patients with diabetes: the 2008 Canadian diabetes association guidelines. CMAJ 2008, 179(9):920-926.
5. LIPID Study Group (Long-term Intervention with pravastatin in ischaemic disease) long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002, 359:1379-1387.
6. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004, 364:685-696.
7. Williams K.J., Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995, 15:551-561.
8. Steinberg D. The pathogenesis of atherosclerosis an interpretive history of the cholesterol controversy, part III: mechanistically defining the role of hyperlipidemia in the pathogenesis. J Lipid Res 2005, 46:2037-2051.
9. Biesbroeck R.C., Albers J.J., Wahl P.W., et al. Abnormal composition of high density lipoproteins in non-insulin-dependent diabetics. Diabetes 1982, 31:126-131.
10. Taskinen M.R. Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes 1992, 41(2):12-17.
11. Persegol L., Verges B., Foissac M., Gambert P., Duvillard L. Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidized LDL on endothelium-dependent vasorelaxation. Diabetologia 2006, 49:1380-1386.
12. Assmann G., Gotto A.M. HDL cholesterol and protective factors in atherosclerosis. Circulation 2004, 109(23 Suppl. 1):III8-III14.
13. Florentin M., Liberopoulos E.N., Wierzbicki A.S., Mikhailidis D.P. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008, 23:370-378.
14. Nissen S.E., Tsunoda T., Tuzcu E.M., et al. Effect of recombinant ApoA-1 Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292-2300.
15. Badimon J.J., Badimon L., Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma traction in the cholesterol-fed rabbit. J Clin Invest 1990, 85:1234-1241.
16. Chiesa G., Monteggia R., Marchesi M., et al. Recombinant apolipoprotein A1 Milano infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res 2002, 90:974-980.
17. Proctor S.D., Russell J.C. Small animal models of cardiovascular disease: tools for study of roles of the metabolic syndrome, dyslipidemias and atherosclerosis. J Cardiovasc Pathol 2006, 15:318-330.
18. Russell J.C., Graham S.E., Richardson M. Cardiovascular disease in the JCR:LA-cp rat. Mol Cell Biochem 1998, 188:113-126.
19. Elam M.B., Wilcox H.G., Cagen L.M., et al. Increased hepatic VLDL secretion, lipogenesis, and SREBP-1 expression in the corpulent JCR:LA-cp rat. J Lipid Res 2001, 42:2039-2048.
20. Mangat R., Su J., Scott P.G., et al. Chylomicron and apoB48 metabolism in the JCR:LA corpulent rat, a model for the metabolic syndrome. Biochem Soc Trans 2007, 35:477-481.
21. Vine D.F., Takechi R., Russell J.C., Proctor S.D. Impaired postprandial apolipoprotein-B48 metabolism in the obese, insulin-resistant JCR:LA-cp rat: increased atherogenicity for the metabolic syndrome. Atherosclerosis 2007, 190:282-290.
22. Russell J.C., Amy R.M., Graham S.E., et al. Inhibition of atherosclerosis and myocardial lesions in the JCR: LA-cp rat by β, β'-tetramethylhexadecanedioic acid (MEDICA 16). Atherocler Thromb Vasc Biol 1995, 15:918-923.
23. Rye K.A., Garrety K.H., Barter P.J. Changes in the size of reconstituted high density lipoproteins during incubation with cholesteryl ester transfer protein: the role of apolipoproteins. J Lipid Res 1992, 33(2):215-224.
24. Matz C.E., Jonas A. Micellar complexes of human apolipoprotein A-1 with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersion. J Biol Chem 1982, 257:4535-4540.
25. Rye K.A., Hime N.J., Barter P.J. The influence of cholesteryl ester transfer protein on the composition, size, and structure of spherical reconstituted high density lipoproteins. J Biol Chem 1995, 270(1):189-196.
26. Proctor S.D., Vine D.F., Mamo J.C.L. Arterial permeability and efflux of apolipoprotein B-containing lipoproteins assessed by in situ perfusion and three-dimensional quantitative confocal microscopy. Arterioscler Thromb Vasc Biol 2004, 24:2162-2267.
27. Ramsamy T.A., Boucher J., Brown R.J., Yao Z., Sparks D.L. HDL regulates the displacement of hepatic lipase from cell surface proteoglycans and the hydrolysis of VLDL traicylglycerol. J Lipid Res 2003, 44(4):733-741.
28. Kiya Y., Miura S., Imaizumi S., et al. Reconstituted high-density lipoprotein attenuates postinfarction left ventricular remodeling in rats. Atherosclerosis 2009, 203(1):137-144.
29. Drew B.G., Fidge N.H., Gallon-Beaumier G., Kemp B.E., Kingwell B.A. High-density lipoprotein and apolipoprotein A1 increase endothelial NO synthase activity by protein association and multisite phosphorylation. Proc Natl Acad Sci USA 2004, 101(18):6999-7004.
30. Mineo C., Yuhanna I.S., Quon M.J., Shaul P.W. High density lipoprotein-induced endothelial nitric oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem 2003, 278(11):9142-9149.
31. Yuhanna I.S., Zhu y., Cox B.E., et al. High-density lipoprotein binding to scavenger receptor-B1 activates endothelial nitric oxide synthase. Nat Med 2001, 7(7):853-857.
32. Russell J.C., Amy R.M. Early atherosclerotic lesions in a susceptible rat model: the LA/N-corpulent rat. Atherosclerosis 1986, 60:119-129.
33. Barter P.J., Nicholls S.J., Rye K.A., et al. Antiinflammatory properties of HDL. Circ Res 2004, 95:764-772.
34. Cockerill G.W., Rye K.A., Gamble J.R., Vadas M.A., Barter P.J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995, 15:1987-1994.
35. Calabresi L., Franceschini G., Sirtori C.R., et al. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun 1997, 238:61-65.
36. Park S., Park J., Kang J., Kang Y. Involvement of transcription factors in plasma HDL protection against TNF-α-induced vascular cell adhesion molecule-1 expression. Int J Biochem Cell Biol 2003, 35:168-182.
37. Spieker L., Sudano I., Hurlimann D., et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002, 105:1399-1402.
38. Tardif J., Gregoire j., L'Allier P. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007, 297:1675-1682. ERASE Investigators.
39. Bursill C.A., Castro M.L., Beattie D.T., et al. High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo. Arterioscler Thromb Vasc Biol 2010, 30:1773-1778.
40. Nicholls S.J., Dusting G.J., Curti B., et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and pro-inflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1995, 111:1543-1550.
41. Xia P., Vadas M.A., Rye K.A., Barter P.J., Gamble J.R. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J Biol Chem 1999, 274:33143-33147.